MNKのチャート
MNKの企業情報
| symbol | MNK |
|---|---|
| 会社名 | Mallinckrodt Plc （MNK マリンクロット） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 マリンクロット（Mallinckrodt public limited company）は世界的な特殊医薬品会社である。同社はブランド付きとジェネリックスペシャリティ医薬品、医薬品有効成分（API）と画像診断薬の開発・製造・マーケティング・販売を行っている。同社はAPI製品を使用してジェネリック医薬品を製造して、その他製薬会社に販売する。同社は２つの事業区分を通して運営している。スペシャルティ医薬品事業はそのブランドビジネスを通して、｢EXALGO｣（ヒドロモルフォン塩酸）放錠及び｢GABLOFEN｣（バクロフェン注射）を含める医薬品を開発・製造・販売している。グローバルメディカルイメージング事業は造影剤とデリバリーシステム（CMDS）を開発・製造・販売している。平成25年6月28日、Covidien plcは医薬品事業の分離を完了し、それを同社に譲渡した。 マリンクロットはアイルランドのバイオ医薬品・画像診断剤メ―カ―。特殊医薬品部門はブランド医薬品、バイオ医薬品に加え、オピオイドやアセトアミノフェンなどの医療用麻薬を成分とする医薬品原薬を扱う。グロ―バル医療画像部門は造影剤、ドラッグデリバリ―システム、放射性医薬品を開発、製造、販売。 |
| 本社所在地 | 3 Lotus Park The Causeway Staines-Upon-Thames Surrey TW18 3AG GBR |
| 代表者氏名 | Mark C. Trudeau |
| 代表者役職名 | President Chief Executive Officer Director |
| 電話番号 | +44 1784-63-6700 |
| 設立年月日 | 41275 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 3700人 |
| url | www.mallinckrodt.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 1131.90000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 1815.39900 |
| 売上高 | 売上高（百万ドル） 3215.60000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7558.09900 |
| 当期純利益 | 当期純利益（百万ドル） -3630.40000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 28 December 2018 Mallinckrodt PLC revenues remained flat at $3.22B. Net loss before extraordinary items totaled $3.63B vs. income of $1.31B. Revenues reflect Other segment increase of 55% to $124.3M Europe/Middle EastAfrica segment increase of 6% to $256.8M also reflect United States segment decrease of 2% to $2.83B. Net loss reflects Corporate/Unallocated segment loss increase from $966.6M to $4.9B. |
MNKのテクニカル分析
MNKのニュース
Baltimore receives nearly $475,000 in settlement with opioid manufacturer Mallinckrodt 2023/04/20 03:44:15 The Baltimore Sun
Baltimore received about $475,000 in settlement money from drugmaker Mallinckrodt Plc, the mayor’s office said in a Wednesday news release.
ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK 2023/04/16 23:00:00 PR Newswire
NEW YORK, April 16, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially…
ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK 2023/04/16 23:00:00 Kwhen Finance
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK 2023/04/13 22:00:00 Kwhen Finance
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK 2023/04/02 12:30:00 NewMediaWire
WHY: New York, NY - (NewMediaWire) - April 02, 2023 - Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Mallinckrodt securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=13407 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.WHAT IS THIS ABOUT: On March 17, 2023, The Buxton Helmsley Group, Inc., a “New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc.” issued two open letters and press releases, later corrected.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK 2023/04/02 12:30:00 NewMediaWire
WHY: New York, NY - (NewMediaWire) - April 02, 2023 - Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Mallinckrodt securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=13407 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.WHAT IS THIS ABOUT: On March 17, 2023, The Buxton Helmsley Group, Inc., a “New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc.” issued two open letters and press releases, later corrected.
Silence stock rises ~10% on deal to buy back rights to 2 drug targets from Mallinckrodt 2023/03/28 12:11:00 Seeking Alpha
Silence Therapeutics (SLN) will buy back rights to two siRNA drug targets for complement-mediated diseases from Mallinckrodt. Read more here
Silence Therapeutics to Buyback siRNA Complement Assets 2023/03/28 11:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced it will be acquiring back exclusive worldwide rights to two siRNA drug targets under the collaboration agreement with Mallinckrodt Pharmaceuticals for complement-mediated diseases. Under the terms of the agreement, Silence will not mak
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK 2023/03/27 23:26:00 Kwhen Finance
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK 2023/03/27 23:26:00 PR Newswire
NEW YORK, March 27, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued…
Mallinckrodt plc (MNK) Q4 2022 Earnings Call Transcript 2023/02/28 15:43:08 Seeking Alpha
Mallinckrodt plc (NYSE:NYSE:MNK) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ETCompany ParticipantsDaniel Speciale - Global Corporate Controller and Chief Investor Relations…
Mallinckrodt Non-GAAP EPS of $4.07, revenue of $489.3M, initiates FY23 outlook 2023/02/28 12:17:13 Seeking Alpha
Mallinckrodt press release (MNK): Q4 Non-GAAP EPS of $4.07.Revenue of $489.3M (-18.1% Y/Y).Adjusted EBITDA was $175.5 millionFiscal 2023 Guidance: Adjusted EBITDA is $510 Million to…
Holding stocks: Monster Beverage Corporation (NASDAQ:MNST -1.42%), Mallinckrodt plc (AMEX:MNK 1.24%) 2023/02/25 12:39:49 Stock Equity
MNST has seen its SMA50 which is now -0.78%. In looking the SMA 200 we see that the stock has seen a 6.71%. MNK has seen its SMA50 which is … The post Holding stocks: Monster Beverage Corporation (NASDAQ:MNST -1.42%), Mallinckrodt plc (AMEX:MNK 1.24%) appeared first on Stocks Equity .
Current Active Runners: Onconova Therapeutics, Inc. (NASDAQ:ONTX), Mallinckrodt plc (AMEX:MNK) 2023/02/23 16:26:26 Stock Equity
ONTX has seen its SMA50 which is now 2.69%. In looking the SMA 200 we see that the stock has seen a -12.77%. MNK has seen its SMA50 which is … The post Current Active Runners: Onconova Therapeutics, Inc. (NASDAQ:ONTX), Mallinckrodt plc (AMEX:MNK) appeared first on Stocks Equity .
Paracetamol Market to See Major Growth by 2030: Mallinckrodt, Anqiu Lu''an, Parchem Fine & Specialty Chemicals 2023/02/20 19:21:00 SBWire
The Paracetamol market size is estimated to increase by USD 216.8 Million at a CAGR of 3.3% from 2023 to 2028. The report includes historic market data from 2017 to 2022E. Currently,the market value is pegged at USD 991.5 Million. Pune, Maharashtra -- ( SBWIRE ) -- 02/20/2023 -- According to HTF Market Intelligence, the Global Paracetamol market to witness a CAGR of 3.3% during forecast period of 2023-2028. The market is segmented by Application (Headache and Fever, Cold and Cough, Muscle Cramps) by Type (Tablets & Capsules, Liquid) and by Geography (North America, South America, Europe, Asia Pacific, MEA). Gain more insights into the market size, Request a Sample Report @ https://www.htfmarketintelligence.com/sample-report/global-paracetamol-market Paracetamol is one of the most popular and normally used analgesic and antipyretic drugs around the world available without a prescription. People who are suffering with bronchial asthma, peptic ulcer disease, hemophilia, salicylate-sensitized people and children under 12 years of age and to pregnant or breastfeeding women should not use non-steroidal drug.